135 related articles for article (PubMed ID: 7996383)
1. Investigation of synergism with combinations of dibromopropamidine isethionate or propamidine isethionate and polymyxin B.
Richards MR; Xing DK
J Pharm Pharmacol; 1994 Jul; 46(7):563-6. PubMed ID: 7996383
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the antibacterial activities of combinations of sulfonamides, trimethoprim, dibromopropamidine, and silver nitrate compared with their uptakes by selected bacteria.
Richards RM; Taylor RB; Xing DK
J Pharm Sci; 1991 Sep; 80(9):861-7. PubMed ID: 1800710
[TBL] [Abstract][Full Text] [Related]
3. Investigation of cell envelope damage to Pseudomonas aeruginosa and Enterobacter cloacae by dibromopropamidine isethionate.
Richards RM; Xing JZ; Gregory DW; Marshall D
J Pharm Sci; 1993 Sep; 82(9):975-7. PubMed ID: 8229701
[TBL] [Abstract][Full Text] [Related]
4. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli.
Critchley IA; Sahm DF; Kelly LJ; Karlowsky JA
Chemotherapy; 2003 May; 49(1-2):44-8. PubMed ID: 12714810
[TBL] [Abstract][Full Text] [Related]
5. Investigation of synergism between combinations of ciprofloxacin, polymyxin, sulphadiazine and p-aminobenzoic acid.
Richards RM; Xing DK
J Pharm Pharmacol; 1993 Mar; 45(3):171-5. PubMed ID: 8097773
[TBL] [Abstract][Full Text] [Related]
6. In vitro interactions of neomycin sulfate, bacitracin, and polymyxin B sulfate.
Booth JH; Benrimoj SI; Nimmo GR
Int J Dermatol; 1994 Jul; 33(7):517-20. PubMed ID: 7928043
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of gram-negative bacteria to the synergistic bactericidal action of serum and polymyxin B nonapeptide.
Viljanen P; Käyhty H; Vaara M; Vaara T
Can J Microbiol; 1986 Jan; 32(1):66-9. PubMed ID: 3008971
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.
Cai Y; Lim TP; Teo J; Sasikala S; Lee W; Hong Y; Chan EC; Tan TY; Tan TT; Koh TH; Hsu LY; Kwa AL
Antimicrob Agents Chemother; 2016 Sep; 60(9):5238-46. PubMed ID: 27324776
[TBL] [Abstract][Full Text] [Related]
9. The antimicrobial spectrum of Xeroform
Barillo DJ; Barillo AR; Korn S; Lam K; Attar PS
Burns; 2017 Sep; 43(6):1189-1194. PubMed ID: 28641915
[TBL] [Abstract][Full Text] [Related]
10. Synergism of the antimicrobial agents miconazole, bacitracin and polymyxin B.
Cornelissen F; Van den Bossche H
Chemotherapy; 1983; 29(6):419-27. PubMed ID: 6317296
[TBL] [Abstract][Full Text] [Related]
11. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of miconazole and polymyxin B on microbial pathogens.
Pietschmann S; Hoffmann K; Voget M; Pison U
Vet Res Commun; 2009 Aug; 33(6):489-505. PubMed ID: 19085068
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
14. [Guidelines for testing and rating hand decontamination preparations].
Borneff J; Eggers HJ; Exner M; Grün L; Gundermann KO; Hammes W; Heeg P; Höffler U; Lammers T; Primavesi CA
Zentralbl Bakteriol Mikrobiol Hyg B Umwelthyg Krankenhaushyg Arbeitshyg Prav Med; 1986 Oct; 182(5-6):562-70. PubMed ID: 3101326
[No Abstract] [Full Text] [Related]
15. Is transmission electron microscopy (TEM) a promising approach for qualitative and quantitative investigations of polymyxin B and miconazole interactions with cellular and subcellular structures of Staphylococcus pseudintermedius, Escherichia coli, Pseudomonas aeruginosa and Malassezia pachydermatis?
Voget M; Lorenz D; Lieber-Tenorio E; Hauck R; Meyer M; Cieslicki M
Vet Microbiol; 2015 Dec; 181(3-4):261-70. PubMed ID: 26527257
[TBL] [Abstract][Full Text] [Related]
16. Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination.
Kassamali Z; Prince RA; Danziger LH; Rotschafer JC; Rhomberg PR; Jones RN
Antimicrob Agents Chemother; 2015 Dec; 59(12):7823-5. PubMed ID: 26392511
[TBL] [Abstract][Full Text] [Related]
17. [Study of combinations of antimicrobial agents. Development of the method].
Martin H; Maris P
Ann Pharm Fr; 1993; 51(4):175-85. PubMed ID: 8154787
[TBL] [Abstract][Full Text] [Related]
18. An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics.
Otto RG; van Gorp E; Kloezen W; Meletiadis J; van den Berg S; Mouton JW
Int J Antimicrob Agents; 2019 Jan; 53(1):34-39. PubMed ID: 30240838
[TBL] [Abstract][Full Text] [Related]
19. Synergy of polymyxin B, tigecycline and meropenem against carbapenem-resistant Enterobacter cloacae complex isolates.
Alves PH; Boff RT; Barth AL; Martins AF
Diagn Microbiol Infect Dis; 2019 May; 94(1):81-85. PubMed ID: 30638946
[TBL] [Abstract][Full Text] [Related]
20. In vitro studies of synergistic interaction between aztreonam and cefoperazone.
Borowski J; Zaremba M; Feliński J
Chemioterapia; 1987 Jun; 6(2 Suppl):109-10. PubMed ID: 3151329
[No Abstract] [Full Text] [Related]
[Next] [New Search]
